CD274 and melanoma: Among the mAbs approved by the US FDA nivolumab (Opdivo) and pembrolizumab (Keytruda), are PD-1 blockers and recommended for treating metastatic NSCLC and melanoma, respectively in 2014 (54, 55) and atezolizumab (Tecentriq), a PD-L-1 inhibitor antibody was approved in 2016 for treating metastatic NSCLC and urothelial cancer (56).